Iniciar sesión Regístrese gratis

Midatech Pharma Plc Ingresos

¿Qué es el Ingresos de Midatech Pharma Plc?

El Ingresos de Midatech Pharma Plc es -£8.16

¿Cuál es la definición de Ingresos?

El ingreso neto disponible para los accionistas comunes es igual al ingreso neto menos los dividendos preferentes pagados.

Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.

Ingresos de compañías en Sector Health Care en LSE en comparadas con Midatech Pharma Plc

¿Qué hace Midatech Pharma Plc?

Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Empresas con ingresos similar a Midatech Pharma Plc